← Back to Search
MCF-7 Breast Cancer Cells Overexpressing Transfectedc-erbB-2 Have Anin Vitro Growth Advantage In Estrogen-depleted Conditions And Reduced Estrogen-dependence And Tamoxifen-sensitivityin Vivo
Y. Liu, D. El-Ashry, D. Chen, I. Y. Ding, F. Kern
Published 2004 · Biology, Medicine, Chemistry
Download PDFAnalyze on Scholarcy
SummaryAc-erbB-2 expression vector was transfected into the estrogen receptor positive (ER+) MCF-7 human breast cancer cell line to determine if overexpression of this transmembrane tyrosine kinase could increase the malignant phenotype of this cell line. Loss of transfectedc-erbB-2 expression was observed when cells were carried in medium containing estrogen. Homogeneous populations stably overexpressing levels of the 185 kDac-erbB-2 observed in the SKBR-3 a breast cancer cell line which overexpressesc-erbB-2 as a result of gene amplification could be obtained by continually maintaining the transfected cell lines in estrogen-free conditions. Levels of constitutively activatedc-erbB-2 varied among clonal isolates. Whereas some over-expressing lines did acquire the ability to form transient tumor nodules in ovariectomized nude mice without estrogen supplementation, as well as in mice that received the antiestrogen tamoxifen, one cell line that exhibited the highest levels of constitutively activatedc-erbB-2 was able to form static tumors of a larger size under both conditions. This same cell line formed progressively growing tumors in estrogen-supplemented mice that were much larger than observed in mice injected with control cell lines, and also showed reduced sensitivity to antiestrogensin vitro, but it continued to have a low metastatic phenotype. These results suggest that signal transduction mediated by thec-erbB-2 tyrosine kinase can partially overcome the estrogen dependence of ER+ breast cancer cells for growth and thatc-erbB-2 overexpression confers a selective advantage to such cells in the absence of estrogen.
This paper references
A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.
G. Scott (1993)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
Oncogenic potential of erbB-2 in human mammary epithelial cells.
J. Pierce (1991)
Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.
M. Kraus (1987)
Identification of Heregulin, a Specific Activator of p185erbB2
W. E. Holmes (1992)
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
C. Shih (1981)
Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.
A. Samanta (1994)
MCF - 7 breast carcinoma cells overexpressing recombinant FGF - I cDNAs with or without an appended signal peptide form vascularized , metastatic tumors in ovariectomized nude mice
S Antoniotti (1994)
Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
P. P. D. Fiore (1987)
expression by estrogens in human breast cancer cells
CR King (1990)
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
M. M. Bradford (1976)
Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma.
R. Dickson (1987)
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture.
W. Welshons (1987)
Human breast carcinoma cells in continuous culture: a review.
L. Engel (1978)
Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
J. Sarup (1991)
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
R. Hudziak (1987)
17α-Estradiol Is a Biologically Active Estrogen in Human Breast Cancer Cells in Tissue Culture*
D. Edwards (1980)
Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships.
E. Peles (1993)
Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock.
C. R. King (1989)
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
C. T. Guy (1992)
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.
R. Lupu (1990)
Tamoxifen upregulates c - erbB2 expression in oestrogen - responsive breast cancer cells in vitro
Sainsbury JRC (1992)
The neu oncogene encodes an epidermal growth factor receptor-related protein
C. Bargmann (1986)
Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens.
B. Katzenellenbogen (1987)
Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression.
B. Gusterson (1992)
Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.
G. Plowman (1990)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
C. Benz (2005)
Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3.
C. R. King (1988)
The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.
O. Alper (1990)
A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.
S. Bacus (1992)
Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.
N. Lemoine (1990)
A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization.
O. Kashles (1991)
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.
R. Clarke (1989)
Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation.
A. Basu (1989)
A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells.
Y. Z. Lin (1991)
An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
B. Langton (1991)
Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.
G. Plowman (1993)
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
L. Coussens (1985)
EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
D. F. Stern (1988)
Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
R. Lodato (1990)
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
M. J. van de Vijver (1988)
Low metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene.
Keisuke Yusa (1990)
Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.
J. Price (1990)
Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.
D. Miller (1994)
Isolation of the neu / HER - 2 stimulatory ligand : a 44 kd glycoprotein that induces differentiation of mammary tumor
SS Bacus (1992)
Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice.
S. W. Mcleskey (1993)
onstration of ligand - dependent signaling by the erb - B 3 tyrosine kinase and its constitutive activation in human breast tumor cells
MH Kraus (1993)
The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3
Özge Alper Gürgen (1991)
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
C. Bargmann (1986)
Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells.
R. Dickson (1986)
The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.
F. Lonardo (1990)
Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells.
D. Yu (1991)
Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ.
J. Kurebayashi (1993)
Epidermal growth factor inhibits the growth of A 431 epidermoid carcinoma in serum - free cell culture
M Kan (1982)
Immunologic analysis of human breast cancer progesterone receptors. 1. Immunoaffinity purification of transformed receptors and production of monoclonal antibodies.
P. A. Estes (1987)
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.
L. Read (1990)
dermal growth factor receptors and oestrogen receptors in human breast cancer
RB Dickson (1985)
Heparin-binding growth factor type 1 (acidic fibroblast growth factor): a potential biphasic autocrine and paracrine regulator of hepatocyte regeneration.
M. Kan (1989)
Additive effects of c‐erbB‐2, c‐Ha‐ras, and transforming growth factor‐α genes on in vitro transformation of human mammary epithelial cells
F. Ciardiello (1992)
c-erbB-2 oncogene as a prognostic marker in breast cancer.
T. Perren (1991)
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
D. Allred (1992)
An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation.
T. Flickinger (1992)
Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.
M. Kraus (1993)
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. D. Di Fiore (1987)
High-efficiency transformation of mammalian cells by plasmid DNA.
C. Chen (1987)
H - beta estradiol is a biologically active estrogen in human breast cancer cells in tissue culture
DR Edwards (1980)
Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Y. Zhai (1993)
A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells.
Lin Yz (1991)
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
C. Wright (1992)
Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells.
C. Dati (1990)
Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells.
B. D'souza (1993)
Mechanisms of normal and malignant breast epithelial growth regulation.
M. Lippman (1989)
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.
W. Gullick (1991)
EPIDERMAL-GROWTH-FACTOR RECEPTORS AND ESTROGEN-RECEPTORS IN HUMAN-BREAST CANCER
J. Sainsbury (1985)
Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
E. Peles (1992)
EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER
Jrc Sainsbury (1985)
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
E. Berns (1992)
Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
F. Ciardiello (1990)
Fibroblast growth factor 4 transfection of MCF - 7 cells produces cell lines that are tu - morigenic and metastatic in ovariectomized or tamoxifen - treated athymic nude mice
YZ Lin (1993)
Inhibition of c - erbB2
Induc ~ tion of epidermal growth factor - related polypeptides by 17 beta - estradiol in MCF - 7 human breast cancer cells
DW Barnes (1986)
Heregulin induces tyrosine phosphorylation of HER4/p180erbB4
G. Plowman (1993)
Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro.
S. Antoniotti (1992)
This paper is referenced by
Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol.
W. Yue (2002)
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
N. Normanno (2005)
Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
S. Glaros (2006)
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
R. Nicholson (2005)
Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
J. García-Saenz (2006)
Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.
M. Toneff (2010)
Serum HER-2/neu and R esponse t o t he A romatase I nhibitor Letrozole V ersus T amoxifen
A. Lipton (2003)
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
A. Buzdar (2009)
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level
M. Campiglio (2004)
Inducible expression of FGF-3 in mouse mammary gland
E. S. Ngan (2002)
Protein Kinase C Alpha in Breast Cancer: A Focus on Endocrine Resistant and Triple Negative Breast Cancer
D. Tonetti (2016)
Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family
Søren S. Larsen (2004)
Peptide-based B-cell epitope vaccines targeting HER-2/neu
Joan T. Garrett (2007)
Oncogenic protein tyrosine kinases
S. Ménard (2004)
AMeta-Analysis on the Interaction between HER-2 Expression and Response to EndocrineTreatment in Advanced Breast Cancer
M. Laurentiis (2005)
Endometrial Cancer Prevention
F. A. Garcia (2008)
Breast cancer with HER 2 overexpressed. From laboratory to clinical practice
S. Ménard (2006)
Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women
R. Singhai (2011)
Prognostic and predictive factors in human breast cancer
S. Maunglay (2007)
HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
S. Pupa (2005)
Cells HER 2-overexpressing , Tamoxifen-resistant Breast Cancer Kinases Enhances Tamoxifen Action against B-2 ) and Mitogen-activated Protein erb ( neu Inhibition of HER 2 / Updated
H. Kurokawa (2000)
6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R
P.T.P. Kaumaya (2017)
The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations : a crosstalk with potential to predict tamoxifen resistance in breast cancer
J. Bostner (2013)
Notch Signaling Is Important in the Survival, Proliferation, and Self-Renewal of the Putative Breast Cancer Stem Cell Population
P. Grudzien (2010)
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.
R. Bakin (2003)
HER2 Overexpression Attenuates the Antiproliferative Effect of Aromatase Inhibitor in MCF-7 Breast Cancer Cells Stably Expressing Aromatase
I. Shin (2009)
Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.
K. W. Crawford (2002)
Predicting endocrine therapy responsiveness in breast cancer.
C. Ma (2009)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
Biologic and therapeutic role of HER2 in cancer
S. Ménard (2003)
Role of oestrogen receptor phosphorylation in the growth of endocrine-responsive and anti-oestrogen-resistant breast cancer cell lines
D. Britton (2005)
Transfected MCF-7 cells as a model for breast cancer progression
F. G. Kern (2004)See more